European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025
Transcatheter management of left-sided valvular heart disease following heart transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hinkov Hristian, Roehrich Luise, Lee Chong Bin, Klein Christoph, Kukucka Marian, Merke Nicolas, Falk Volkmar, Dreger Henryk, Knosalla Christoph, Schoenrath Felix, Unbehaun Axel
Аннотация
OBJECTIVES: Aortic stenosis (AS) and mitral regurgitation (MR) are rare in heart transplant (HTx) recipients, but their incidence increases with extended post-transplant survival. This study assesses the safety, efficacy and outcomes of transcatheter interventions in this high-risk population.
METHODS: An institutional series of HTx patients undergoing a transcatheter aortic valve implant (TAVI) or mitral transcatheter edge-to-edge repair (M-TEER) from March 2015 through April 2024 was analysed retrospectively. Both elective cases and patients in cardiac decompensation/cardiogenic shock were included. There were no exclusion criteria. Primary outcomes were echocardiographic allograft function and Valve Academic Research Consortium 3 (VARC-3)/Mitral Valve Academic Research Consortium (MVARC) success and safety composite end points. Secondary outcomes included symptom change, complications and survival.
RESULTS: A total of 15 consecutive patients were included in the analysis. Nine patients underwent TAVI and 6 had M-TEER. The median age was 56 years, with a median of 17 years from HTx to valve intervention. A total of 46.7% (7/15) of the procedures were considered urgent/emergency. Improvements were noted in the left ventricular ejection fraction, systolic pulmonary artery pressure and tissue Doppler peak contraction velocity. The VARC-3/MVARC technical success was 100%; device success for TAVI was 93.3% and 83.3% for M-TEER. VARC-3 early safety was 66.7% for TAVI, and MVARC procedural success was 83.3% for M-TEER; 86.7% showed improved functional status. Median survival was 800 days.
CONCLUSIONS: TAVI and M-TEER were feasible and efficient in improving echocardiographic allograft function. Elective procedures were associated with a median survival of over 2 years. Survival outcomes varied based on procedure urgency. Close monitoring of AS/MR seems crucial in HTx patients, with timely intervention prior to decompensation/shock. Further multicentre studies are needed to establish management guidelines for AS/MR in HTx recipients.
METHODS: An institutional series of HTx patients undergoing a transcatheter aortic valve implant (TAVI) or mitral transcatheter edge-to-edge repair (M-TEER) from March 2015 through April 2024 was analysed retrospectively. Both elective cases and patients in cardiac decompensation/cardiogenic shock were included. There were no exclusion criteria. Primary outcomes were echocardiographic allograft function and Valve Academic Research Consortium 3 (VARC-3)/Mitral Valve Academic Research Consortium (MVARC) success and safety composite end points. Secondary outcomes included symptom change, complications and survival.
RESULTS: A total of 15 consecutive patients were included in the analysis. Nine patients underwent TAVI and 6 had M-TEER. The median age was 56 years, with a median of 17 years from HTx to valve intervention. A total of 46.7% (7/15) of the procedures were considered urgent/emergency. Improvements were noted in the left ventricular ejection fraction, systolic pulmonary artery pressure and tissue Doppler peak contraction velocity. The VARC-3/MVARC technical success was 100%; device success for TAVI was 93.3% and 83.3% for M-TEER. VARC-3 early safety was 66.7% for TAVI, and MVARC procedural success was 83.3% for M-TEER; 86.7% showed improved functional status. Median survival was 800 days.
CONCLUSIONS: TAVI and M-TEER were feasible and efficient in improving echocardiographic allograft function. Elective procedures were associated with a median survival of over 2 years. Survival outcomes varied based on procedure urgency. Close monitoring of AS/MR seems crucial in HTx patients, with timely intervention prior to decompensation/shock. Further multicentre studies are needed to establish management guidelines for AS/MR in HTx recipients.